Sign In
Buy GSK
$50.67
-1.48 (-2.84%)
At Close: Jun 18, 2026
GSK: I Foresee Only Very Modest Upside Here Even If Blenrep Gets FDA Approval
12:41pm, Monday, 28'th Jul 2025
GSK's diversified portfolio and strong HIV/specialty medicines offer stability, but growth prospects remain modest amid stiff competition and legal overhangs. Despite a robust pipeline and management'
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of GSK plc – GSK
11:47am, Monday, 28'th Jul 2025
NEW YORK, July 28, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of GSK plc (“GSK” or the “Company”) (NYSE: GSK). Such investors are advised to contac
GSK shares rise on $500m drug deal with China's Hengrui
06:39am, Monday, 28'th Jul 2025
Shares in GSK PLC (LSE:GSK, NYSE:GSK) rose in morning trading after the pharmaceutical group announced a $500 million collaboration with Hengrui Pharma to co-develop up to 12 experimental medicines,
GSK to make $500m down payment on Chinese licensing deal worth up to $12bn
02:49am, Monday, 28'th Jul 2025
GSK PLC (LSE:GSK, NYSE:GSK) has agreed to pay $500 million in upfront fees to Chinese drugmaker Hengrui Pharma as part of a wide-ranging collaboration to develop up to 12 experimental medicines in a
Jiangsu Hengrui grants GSK global rights to drug portfolio in $500 million deal
10:35pm, Sunday, 27'th Jul 2025
China's Jiangsu Hengrui Pharmaceuticals said on Monday it has agreed to license the global rights of its HRS-9821 drug and 11 other programmes to GlaxoSmithKline Intellectual Property (GSK) for $500 m
Includes license for potential best-in-class PDE3/4 inhibitor (HRS-9821) in clinical development for treatment of COPD Additional 11 programmes to be developed by Hengrui Pharma and optioned by GSK fo
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of GSK plc - GSK
10:00am, Sunday, 27'th Jul 2025
NEW YORK , July 27, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of GSK plc ("GSK" or the "Company") (NYSE: GSK). Such investors are advised to contact Danielle P
GSK's blood cancer drug gets EU approval for multiple myeloma
12:27pm, Thursday, 24'th Jul 2025
British drugmaker GSK said on Thursday the European Union has approved the company's blood cancer drug Blenrep for the treatment of relapsed or refractory multiple myeloma.
GSK sponsors 2025 National Senior Games as part of Sideline RSV campaign to raise awareness of RSV in older adults
09:00am, Thursday, 24'th Jul 2025
PHILADELPHIA--(BUSINESS WIRE)-- #Adult--GSK sponsors 2025 National Senior Games as part of Sideline RSV campaign to raise awareness of RSV in older adults.
US FDA extends review of GSK's blood cancer drug
12:15pm, Wednesday, 23'rd Jul 2025
The U.S. Food and Drug Administration has extended its review of GSK's blood cancer drug Blenrep as a combination treatment, the company said on Wednesday.
GSK (GSK) Reports Next Week: Wall Street Expects Earnings Growth
11:08am, Wednesday, 23'rd Jul 2025
Glaxo (GSK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of GSK plc – GSK
10:00am, Wednesday, 23'rd Jul 2025
NEW YORK, July 23, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of GSK plc (“GSK” or the “Company”) (NYSE: GSK). Such investors are advised to contac
FDA Advisory Panel Votes Against Approval of GSK's Blenrep Combo
11:41am, Friday, 18'th Jul 2025
GSK stock falls as an FDA panel votes against its Blenrep combo, casting doubt on U.S. approval hopes.
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
09:50am, Friday, 18'th Jul 2025
Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.
GSK Shares Drop After FDA Committee Vote Leaves Cancer-Drug Comeback in Doubt
08:44am, Friday, 18'th Jul 2025
The pharmaceutical company said it remained confident in the benefit and risk profile of Blenrep and will continue to work with the FDA.
